ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ACAD Acadia Pharmaceuticals Inc

16.40
0.09 (0.55%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Acadia Pharmaceuticals Inc NASDAQ:ACAD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.09 0.55% 16.40 16.40 25.89 16.74 16.265 16.45 1,168,199 05:00:00

ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

05/05/2020 9:05pm

Business Wire


Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Acadia Pharmaceuticals Charts.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences:

  • 2020 BofA Securities Health Care Conference on Tuesday, May 12, 2020, at 11:00 a.m. Eastern Time.
  • 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020, at 1:55 p.m. Eastern Time.

These conferences will both be held virtually. Live webcasts of ACADIA’s presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, major depressive disorder, the negative symptoms of schizophrenia, and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

Media Contact: ACADIA Pharmaceuticals Inc. Stephanie Fagan (858) 212-0534 media@acadia-pharm.com

Investor Contact: ACADIA Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 ir@acadia-pharm.com

1 Year Acadia Pharmaceuticals Chart

1 Year Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

1 Month Acadia Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock